{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:49Z","timestamp":1792007749199,"version":"4.4.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81300251"],"award-info":[{"award-number":["81300251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0161792","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T13:53:56Z","timestamp":1472133236000},"page":"e0161792","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials"],"prefix":"10.1371","volume":"11","author":[{"given":"Chongyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"R Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"G Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref3","first-page":"229","article-title":"Nonalcoholic fatty liver disease and the metabolic syndrome","volume":"54","author":"G Marchesini","year":"2006","journal-title":"Minerva Cardioangiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"H Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.2174\/1381612811319290003","article-title":"Cardiovascular and systemic risk in nonalcoholic fatty liver disease\u2014atherosclerosis as a major player in the natural course of NAFLD","volume":"19","author":"A Lonardo","year":"2013","journal-title":"Curr Pharm Des"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e111808","DOI":"10.1371\/journal.pone.0111808","article-title":"Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits","volume":"9","author":"A Dudekula","year":"2014","journal-title":"PloS One"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial","volume":"47","author":"S Chen","year":"2015","journal-title":"Dig Liver Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jnutbio.2009.01.021","article-title":"Mukitake mushroom (<italic>Panellus serotinus<\/italic>) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db\/db mice","volume":"21","author":"K Nagao","year":"2010","journal-title":"J Nutr Biochem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.dld.2011.11.010","article-title":"Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis","volume":"44","author":"F Salamone","year":"2012","journal-title":"Dig Liver Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.trsl.2011.12.003","article-title":"Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis","volume":"159","author":"F Salamone","year":"2012","journal-title":"Transl Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature05354","article-title":"Resveratrol improves health and survival of mice on a high-calorie diet","volume":"444","author":"JA Baur","year":"2006","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: the in vivo evidence","volume":"5","author":"JA Baur","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0008-6363(00)00102-4","article-title":"Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes","volume":"47","author":"LM Hung","year":"2000","journal-title":"Cardiovasc Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/157489007780832560","article-title":"Resveratrol: a therapeutic promise for cardiovascular diseases","volume":"2","author":"S Das","year":"2007","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/187152807781696464","article-title":"Anti-inflammatory responses of resveratrol","volume":"6","author":"S Das","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.biochi.2011.08.005","article-title":"Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats","volume":"94","author":"R Schmatz","year":"2012","journal-title":"Biochimie"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha","volume":"127","author":"M Lagouge","year":"2006","journal-title":"Cell"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/db09-0482","article-title":"AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol","volume":"59","author":"JH Um","year":"2010","journal-title":"Diabetes"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2012.01.032","article-title":"Finding a target for resveratrol","volume":"148","author":"RI Tennen","year":"2012","journal-title":"Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.nut.2013.11.016","article-title":"Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation","volume":"30","author":"JM Andrade","year":"2014","journal-title":"Nutrition"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"VS Chachay","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"S Heeb\u00f8ll","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"ref24","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1017\/S0007114515002433","article-title":"The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study","volume":"114","author":"F Faghihzadeh","year":"2015","journal-title":"Br J Nutr"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"F Faghihzadeh","year":"2014","journal-title":"Nutr Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.14218\/JCTH.2015.00019","article-title":"Treatment of nonalcoholic fatty liver disease: the role of medical, surgical, and endoscopic weight loss","volume":"3","author":"VB Popov","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3748\/wjg.v21.i4.1099","article-title":"Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease","volume":"21","author":"LX Qiu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.metabol.2013.03.004","article-title":"Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway","volume":"62","author":"ZQ Wang","year":"2013","journal-title":"Metabolism"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.fct.2013.08.036","article-title":"Resveratrol modulates autophagy and NF-\u03baB activity in a murine model for treating non-alcoholic fatty liver disease","volume":"63","author":"L Li","year":"2014","journal-title":"Food Chem Toxicol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/0929867311320100009","article-title":"Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial","volume":"20","author":"S Bo","year":"2013","journal-title":"Curr Med Chem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/db12-0975","article-title":"High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition","volume":"62","author":"MM Poulsen","year":"2013","journal-title":"Diabetes"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0161792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T11:18:59Z","timestamp":1540207139000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0161792"}},"subtitle":[],"editor":[{"given":"Giovanni","family":"Li Volti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0161792","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}